EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis

Lukas Burghart, Sonja Treiber, David Bauer, Emina Halilbasic, Benedikt S Hofer iD, Mattias Mandorfer iD, Michael Gschwantler, Caroline Schwarz, Michael Trauner, Thomas Reiberger iD, Albert F Stättermayer

Alimentary Pharmacology & Therapeutics · 2026

DOI: 10.1111/apt.70349 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Lukas Burghart und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria. Hauptthemen laut MEDLINE: Hepatitis, Autoimmune, Hypertension, Portal. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Autoimmune hepatitis (AIH) may progress to advanced chronic liver disease (ACLD) with clinically significant portal hypertension (CSPH). In this study, we evaluated the prevalence of different clinical CSPH features and their prognostic impact regarding decompensation, liver transplantation (LTX) and death in patients with AIH.

Method

Patients with confirmed AIH diagnosis (sIAIHG‐Score ≥ 6) managed at the Vienna General Hospital between 2005 and 2023 were retrospectively analysed.

Results

Among 271 included patients (76.4% female) with AIH, n = 60 (22.1%) presented clinical features of CSPH at diagnosis. During a median follow‐up of 7.2 (IQR 2.9–12.7) years, the proportion with CSPH features increased to n = 104 (38.4%). In a multivariable cox regression analysis, both compensated (aHR: 5.77, 95% CI: [1.47–22.71], p = 0.012) and decompensated features of CSPH (aHR: 15.73, 95% CI: [4.17–59.33], p < 0.0001) were associated with an increased risk of LTX/death, whereas complete biochemical response and higher albumin levels were identified as protective factors. The BAVENO‐VII criteria for ruling‐out CSPH (liver stiffness < 15 kPa and platelet count ≥ 150 G/L) identified AIH patients with a negligible 10Y cumulative incidence of hepatic decompensation (0.8%) and a favourable 10Y transplant‐free survival (97.8%). Overall, n = 16 (5.9%) patients died, with n = 10 deaths caused by CSPH‐related complications.

Conclusion

In patients with AIH, clinical features of CSPH reflect the risk of future hepatic decompensation and mortality. Hence, regular screening for CSPH in AIH patients seems warranted to ensure timely initiation of adequate CSPH‐directed treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis, AutoimmuneHypertension, PortalHumansFemaleMaleMiddle AgedRetrospective StudiesPrognosisAdultLiver Transplantation

Stichwörter der Autor:innen

ascitesautoimmune hepatitisliver stiffnessplatelet countportal hypertensionsplenomegalyvarices

Autor:innen und Institutionen

  • Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Klinik Ottakring, Wiener Gesundheitsverbund, Vienna, Austria.
  • Rare Liver Diseases (RALID) Centre of the ERN RARE-LIVER, At the Vienna General Hospital, Vienna, Austria.
  • Vienna Hepatic Hemodynamic Laboratory, Division of Gastroenterology and Hepatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria.
  • Christian Doppler Lab for Portal Hypertension and Liver Fibrosis, Medical University of Vienna, Vienna, Austria.
  • Sigmund Freud University, Vienna, Austria.

ORCID-Profile: Benedikt S Hofer, Mattias Mandorfer, Thomas Reiberger

Zitieren

APA

Burghart, L., Treiber, S., Bauer, D., Halilbasic, E., Hofer, B. S., Mandorfer, M., Gschwantler, M., Schwarz, C., Trauner, M., Reiberger, T., & Stättermayer, A. F. (2026). Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70349

Vancouver

Burghart L, Treiber S, Bauer D, Halilbasic E, Hofer BS, Mandorfer M, et al. Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70349

BibTeX
@article{Burghart2026,
  author = {Burghart, Lukas and Treiber, Sonja and Bauer, David and Halilbasic, Emina and Hofer, Benedikt S and Mandorfer, Mattias and Gschwantler, Michael and Schwarz, Caroline and Trauner, Michael and Reiberger, Thomas and Stättermayer, Albert F},
  title = {Clinical Features of Portal Hypertension and Their Prognostic Implications in Patients With Autoimmune Hepatitis},
  journal = {Alimentary Pharmacology & Therapeutics},
  year = {2026},
  doi = {10.1111/apt.70349}
}
Kostenlos starten →